MedTrace Logo

Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen

NCT02076841 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2017-01-27

No results posted yet for this study

Summary

To evaluate treatment tolerability, adherence and quality of life (QoL) over 1 year in MS (Multiple Sclerosis) participants who have been switched - due to persistent tolerability issues, particularly injection problems - from a subcutaneous injectable disease-modifying treatment (DMT) given several times a week (Rebif, Betaferon or Copaxone) to once weekly Avonex 30 μg given intra-muscularly. Avonex will be applied by the injection device Avonex Pen.

Conditions

  • Relapsing-Remitting Multiple Sclerosis
  • Clinical Isolated Syndrome (CIS)
  • Multiple Sclerosis

Interventions

DEVICE

interferon beta-1a

Administered as specified in the treatment arm

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-02-29
Completion
2016-10-31

Countries

  • Czechia
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02076841 on ClinicalTrials.gov